Update on the evaluation and management of dysphagia in sporadic inclusion body myositis.


Journal

Current opinion in otolaryngology & head and neck surgery
ISSN: 1531-6998
Titre abrégé: Curr Opin Otolaryngol Head Neck Surg
Pays: United States
ID NLM: 9417024

Informations de publication

Date de publication:
01 Dec 2023
Historique:
medline: 3 11 2023
pubmed: 8 9 2023
entrez: 7 9 2023
Statut: ppublish

Résumé

Dysphagia is a common symptom of sporadic inclusion body myositis (IBM), affecting disease trajectory and patient quality-of-life. Despite this, it is considerably understudied. The purpose of this review is to summarize current evidence related to the evaluation and management of dysphagia in IBM. We highlight a patient case involving a multidisciplinary management approach, and we encourage continued exploration of exercises for delaying progression and improving impairments in patients with IBM and dysphagia. Recent investigations confirm that dysphagia in IBM is a debilitating and complex symptom that warrants timely evaluation and management. Further, they highlight the lack of validation of standardized swallowing-related metrics specifically for IBM and the limited evidence supporting a consensus of management approaches. Small scale research and clinical anecdotal data support a multidisciplinary and multipronged patient-centered approach, including rehabilitative exercise protocols, for dysphagia management in IBM. A paucity exists in the literature to effectively guide clinical decision-making for patients with IBM and dysphagia. Given this, it is our belief that a careful multidisciplinary and multipronged patient-centered approach is critical for dysphagia management in IBM. Prospective, longitudinal research on the underlying mechanisms of swallowing dysfunction using advanced and validated swallowing-related outcome measures is urgently needed.

Identifiants

pubmed: 37678324
doi: 10.1097/MOO.0000000000000922
pii: 00020840-990000000-00081
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

362-367

Informations de copyright

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Références

Dimachkie MM, Barohn RJ. Inclusion body myositis. Neurol Clin 2014; 32:629–646.
Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nature Rev Rheumatol 2019; 15:257–272.
Labiet B, Pawlitzki M, Ruck T, et al. The impact of dysphagia in myositis: a systematic review and meta-analysis. J Clin Med 2020; 9:2150.
Ambrocio KR, (Focht) Garand KL, Roy B, et al. Diagnosing and managing dysphagia in inclusion body myositis: a systematic review. Rheumatol 2023; https://doi.org/10.1093/rheumatology/kead194 .
Mohannak N, Pattison G, Hird K, Needham M. Dysphagia in patients with sporadic inclusion body myositis: management challenges. Inter J Gen Med 2019; 12:465–474.
Dimachkie MM, Barohn RJ. Inclusion body myositis. Curr Neurol Neurosci Rep 2013; 13:321.
Zeng R, Schmidt J. Impact and management of dysphagia in inflammatory myopathies. Current Rheumatol Rep 2020; 22:74.
Naddaf E. Inclusion body myositis: update on the diagnostic and therapeutic landscape. Front Neurol eCollection 2022; 13:1020113.
Alfano LN, (Focht) Garand KL, Malandraki GA, et al. Measuring change in inclusion body myositis: clinical assessments versus imaging. Clin Exp Rheumatol 2022; 40:404–413.
Belafsky PC, Mouadeb DA, Rees CJ, et al. Validity and reliability of the Eating Assessment Tool (EAT-10). Ann Otol Rhinol Laryngol 2008; 117:919–924.
Jackson CE, Barohn RJ, Gronseth G, et al. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve 2008; 37:473–476.
Roy B, Lucchini M, Lillekar JB, et al. Current status of clinical outcome measures in inclusion body myositis; a systematised review. Clin Exp Rheumatol 2023; 41:370–378.
Ramdharry G, Morrow J, Hudgens S, et al. Investigation of the psychometric properties of the inclusion body myositis functional rating scale with Rasch analysis. Muscle Nerve 2019; 60:161–168.
Silbergleit AK, Schultz L, Jacobson BH, et al. The Dysphagia Handcap Index: development and validation. Dysphagia 2012; 27:45–52.
Belafksy PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice 2002; 16:274–277.
Brady S, Donzelli J. The modified barium swallow and the functional endoscopic evaluation of swallowing. Otolaryngol Clin North Am 2013; 46:1009–1022.
Pisegna JM, Langmore SE. Parameters of instrumental swallowing evaluations: describing a diagnostic dilemma. Dysphagia 2016; 31:462–472.
Chiba T. Inclusion body myositis with dysphagia diagnosed with pharyngoesophageal high-resolution manometry. ACG Case Rep J 2022; 9:e00850.
Olthoff A, Carstens PO, Zhang S, et al. Evaluation of dysphagia by novel real-time MRI. Neurology 2016; 87:2132–2138.
Rose MR, Jones K, Leong K, et al. Treatment for inclusion body myositis. Cochrane Database Syst Rev 2015; 7:CD001555.
Dalakas MC. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 1998; 51: (Suppl 5): S37–S45.
Taira K, Yamamoto T, Mori-Yoshimura M, et al. Cricopharyngeal bar on videofluoroscopy: high specificity for inclusion body myositis. J Neurol 2021; 268:1016–1024.
Mohannak N, Pattison G, Radich B, et al. Exploring the efficacy of the expiratory muscle strength trainer to improve swallowing in inclusion body myositis: a pilot study. Neuromuscul Disord 2020; 30:294–300.
Garand KL, Beall J, Hill EG, et al. Effects of presbyphagia on oropharyngeal swallowing observed during modified bariums wallow studies. J Nutr Health Aging 2022; 26:973–980.
Benlidayi IC, Gupta L. The pathophysiological effects of exercise in the management of idiopathic inflammatory myopathies: a scoping review. Int J Rehum Dis 2021; 21:896–903.
Oh TH, Brumfield KA, Hoskin TL, et al. Dysphagia in inclusion body myositis. Am J Phys Med Rehabil 2008; 87:883–889.
Malandraki GA, Kauffman A, Hind J, et al. The effects of lingual intervention in a patient with Inclusion Body Myositis and Sjögren's syndrome: a longitudinal case study. Arch Phys Med Rehab 2012; 93:1469–1475.
Singh H, Nene Y, Mehta TR, Govindarajan R. Efficacy of botulinum toxin for treating sialorrhea in neuromuscular conditions. Front Neurol 2020; 11:513.
Witting N, Daugaard D, Prytz S, et al. Botulinum toxin treatment improves dysphagia in patients with oculopharyngeal muscular dystrophy and sporadic inclusion body myositis. J Neurol 2022; 269:4154–4160.
Malandraki GA, Rajappa A, Kantarcigil C, et al. The Intensive Dysphagia Rehabilitation Approach (IDRA) for neurogenic dysphagia: a case-series design. Arch Phys Med Rehab 2016; 97:567–574.

Auteurs

Kendrea L Focht Garand (KLF)

Department of Communication Science and Disorders, University of Pittsburgh, Pittsburgh, Pennsylvania.

Georgia A Malandraki (GA)

Department of Speech, Language, & Hearing Sciences, Purdue University, West Lafayette, Indiana.

Mazen M Dimachkie (MM)

Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH